These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. Lipworth BJ, Aziz I. J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190 [Abstract] [Full Text] [Related]
24. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E, National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Lancet; 2009 Nov 21; 374(9703):1754-64. PubMed ID: 19932356 [Abstract] [Full Text] [Related]
25. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Vatrella A, Ponticiello A, Pelaia G, Parrella R, Cazzola M. Pulm Pharmacol Ther; 2005 Nov 21; 18(2):89-92. PubMed ID: 15649850 [Abstract] [Full Text] [Related]
28. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Kottakis J, Cioppa GD, Creemers J, Greefhorst L, Lecler V, Pistelli R, Overend T, Till D, Rapatz Gn, Le Gros V, Bouros D, Siafakas N. Can Respir J; 2002 Nov 21; 9(2):107-15. PubMed ID: 11972164 [Abstract] [Full Text] [Related]
30. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Eur Respir J; 2003 Jan 21; 21(1):86-94. PubMed ID: 12570114 [Abstract] [Full Text] [Related]
34. Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Yates DH, Kharitonov SA, Barnes PJ. Eur Respir J; 1997 Jul 21; 10(7):1483-8. PubMed ID: 9230234 [Abstract] [Full Text] [Related]
35. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Chest; 2000 Apr 21; 117(4):950-3. PubMed ID: 10767223 [Abstract] [Full Text] [Related]
36. Tolerance to bronchodilating effects of salmeterol in COPD. Donohue JF, Menjoge S, Kesten S. Respir Med; 2003 Sep 21; 97(9):1014-20. PubMed ID: 14509555 [Abstract] [Full Text] [Related]
37. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Grove A, Lipworth BJ. Lancet; 1995 Jul 22; 346(8969):201-6. PubMed ID: 7616798 [Abstract] [Full Text] [Related]
38. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T. Ann Allergy Asthma Immunol; 1999 Feb 22; 82(2):205-11. PubMed ID: 10071526 [Abstract] [Full Text] [Related]
39. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Eur Respir J; 1997 Nov 22; 10(11):2484-9. PubMed ID: 9426083 [Abstract] [Full Text] [Related]
40. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, Kuipers AF, International study group. Can Respir J; 2002 Nov 22; 9(3):178-85. PubMed ID: 12068339 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]